Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Cypionate

FDA-approved product (injectable, injection), marketed as Azmiro, Depo-Testosterone, Testosterone Cypionate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Cypionate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Cypionate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • COMbination of Bipolar Androgen Therapy and Nivolumab

    NCT03554317 · start 2018-09-05

    Registered record
    Registry ID
    NCT03554317
    Conditions
    Castration-resistant Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer
    Interventions
    Testosterone cypionate; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-09-05
    Completion
    2023-01-06
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-resistant Prostate Cancer; Metastatic Prostate Cancer; Prostate Cancer
    InterventionTestosterone cypionate; Nivolumab
    PhasePhase 2
    Registry statusCompleted

  • Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

    NCT03516812 · start 2018-08-29

    Registered record
    Registry ID
    NCT03516812
    Conditions
    Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma
    Interventions
    Laboratory Biomarker Analysis; Olaparib; Quality-of-Life Assessment; Survey Administration; Testosterone Enanthate; Testosterone Cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-29
    Completion
    2024-04-12
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma
    InterventionLaboratory Biomarker Analysis; Olaparib; Quality-of-Life Assessment; Survey Administration +2 more
    PhasePhase 2
    Registry statusCompleted

  • TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

    NCT03325647 · start 2017-11-06

    Registered record
    Registry ID
    NCT03325647
    Conditions
    Klinefelter Syndrome
    Interventions
    Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution; Placebo injectable saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-11-06
    Completion
    2021-05-05
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKlinefelter Syndrome
    InterventionTestosterone Cypionate 200 Milligram/Milliliter Injectable Solution; Placebo injectable saline
    PhasePhase 4
    Registry statusCompleted

  • Subcutaneous vs. Intramuscular Testosterone

    NCT03091348 · start 2017-08-29

    Registered record
    Registry ID
    NCT03091348
    Conditions
    Testosterone Deficiency; Hypogonadism, Male
    Interventions
    Testosterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-08-29
    Completion
    2018-01-02
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTestosterone Deficiency; Hypogonadism, Male
    InterventionTestosterone
    PhasePhase 4
    Registry statusCompleted

  • Testosterone Plus Finasteride Treatment After Spinal Cord Injury

    NCT02248701 · start 2017-04-27

    Registered record
    Registry ID
    NCT02248701
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
    Interventions
    Testosterone Enanthate; Finasteride; Placebo injection; Placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-04-27
    Completion
    2021-08-13
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries +7 more
    InterventionTestosterone Enanthate; Finasteride; Placebo injection; Placebo pill
    PhasePhase 2
    Registry statusTerminated

  • Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

    NCT02995330 · start 2017-02-09

    Registered record
    Registry ID
    NCT02995330
    Conditions
    Prostate Cancer
    Interventions
    Bone marrow transplantation; Cytoxan; testosterone cypionate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-02-09
    Completion
    2021-06-16
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBone marrow transplantation; Cytoxan; testosterone cypionate
    PhasePhase 1
    Registry statusTerminated

  • Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness

    NCT03038919 · start 2016-10

    Registered record
    Registry ID
    NCT03038919
    Conditions
    Critical Illness Polyneuropathies
    Interventions
    Testosterone cypionate; Standard nutrition and physical therapy at ICU
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-10
    Completion
    2018-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness Polyneuropathies
    InterventionTestosterone cypionate; Standard nutrition and physical therapy at ICU
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction

    NCT02803073 · start 2016-08

    Registered record
    Registry ID
    NCT02803073
    Conditions
    Hypogonadism; Acute Myocardial Infarction: Rehabilitation Phase
    Interventions
    Testosterone; Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2016-08
    Completion
    2017-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism; Acute Myocardial Infarction: Rehabilitation Phase
    InterventionTestosterone; Normal Saline
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Subcutaneous Testosterone Project

    NCT02229617 · start 2015-07

    Registered record
    Registry ID
    NCT02229617
    Conditions
    Gender Dysphoria
    Interventions
    Subcutaneous testosterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-07
    Completion
    2016-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGender Dysphoria
    InterventionSubcutaneous testosterone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment

    NCT02408445 · start 2015-05-08

    Registered record
    Registry ID
    NCT02408445
    Conditions
    Klinefelter Syndrome
    Interventions
    testosterone cypionate 200mg/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-05-08
    Completion
    2020-01-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKlinefelter Syndrome
    Interventiontestosterone cypionate 200mg/ml
    PhasePhase 4
    Registry statusCompleted

  • Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

    NCT02286921 · start 2015-01

    Registered record
    Registry ID
    NCT02286921
    Conditions
    Castration Resistant Metastatic Prostate Cancer
    Interventions
    Testosterone cypionate; Enzalutamide; Testosterone Enanthate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01
    Completion
    2020-02-21
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Resistant Metastatic Prostate Cancer
    InterventionTestosterone cypionate; Enzalutamide; Testosterone Enanthate
    PhasePhase 2
    Registry statusCompleted

  • Oral Testosterone for the Treatment of Hypogonadism in Males

    NCT02222558 · start 2014-09

    Registered record
    Registry ID
    NCT02222558
    Conditions
    Hypogonadism
    Interventions
    TSX-002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2015-05
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTSX-002
    PhasePhase 2
    Registry statusCompleted

  • RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

    NCT02090114 · start 2014-08-25

    Registered record
    Registry ID
    NCT02090114
    Conditions
    Prostate Cancer
    Interventions
    Testosterone cypionate; Testosterone Enanthate; Abiraterone acetate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08-25
    Completion
    2021-11-11
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTestosterone cypionate; Testosterone Enanthate; Abiraterone acetate; Enzalutamide
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

    NCT02081300 · start 2014-02

    Registered record
    Registry ID
    NCT02081300
    Conditions
    Male Hypogonadism
    Interventions
    Oral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 %
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-02
    Completion
    2015-05
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Hypogonadism
    InterventionOral testosterone undecanoate, LPCN 1021; Topical testosterone gel 1.62 %
    PhasePhase 3
    Registry statusCompleted

  • Oral Testosterone for the Treatment of Hypogonadism

    NCT01717768 · start 2012-10

    Registered record
    Registry ID
    NCT01717768
    Conditions
    Hypogonadism
    Interventions
    TSX-002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-12
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTSX-002
    PhasePhase 2
    Registry statusCompleted